LOGIN  |  REGISTER
Viking Therapeutics
Amneal Pharmaceuticals

Azenta to Participate in Stephens Annual Investment Conference

November 14, 2024 | Last Trade: US$51.43 0.50 -0.96

BURLINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Stephens Annual Investment Conference, on Wednesday November 20, 2024, which includes a presentation beginning at 1:00 pm CT. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial, Planning & Analysis and Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

Sherry Dinsmore
This email address is being protected from spambots. You need JavaScript enabled to view it.

Azenta logo (PRNewsfoto/Azenta)

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page